Filing Details
- Accession Number:
- 0001104659-20-010935
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-02-05 06:02:41
- Reporting Period:
- 2020-01-31
- Accepted Time:
- 2020-02-05 06:02:41
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1477845 | Annovis Bio Inc. | ANVS | Pharmaceutical Preparations (2834) | 262540421 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1786183 | K. Mark White | C/O Annovis Bio, Inc. 1055 Westlakes Drive, Suite 300 Berwyn PA 19312 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2020-01-31 | 1,734 | $6.00 | 1,734 | No | 4 | P | Direct | |
| Common Stock | Acquisiton | 2020-01-31 | 11,548 | $0.00 | 13,282 | No | 4 | C | Direct | |
| Common Stock | Acquisiton | 2020-01-31 | 34,643 | $0.00 | 47,925 | No | 4 | C | Direct | |
| Common Stock | Acquisiton | 2020-01-31 | 3,252 | $4.80 | 51,177 | No | 4 | C | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | P | Direct | |
| No | 4 | C | Direct | |
| No | 4 | C | Direct | |
| No | 4 | C | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Series A-1 Preferred Stock | Disposition | 2020-01-31 | 16,167 | $0.00 | 11,548 | $0.00 |
| Common Stock | Series A Preferred Stock | Disposition | 2020-01-31 | 48,500 | $0.00 | 34,643 | $0.00 |
| Common Stock | Convertible Note | Disposition | 2020-01-31 | 3,252 | $4.80 | 3,252 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | No | 4 | C | Direct | ||
| 0 | No | 4 | C | Direct | ||
| 0 | No | 4 | C | Direct |
Footnotes
- The reporting person acquired these shares in the initial public offering ("IPO") of Annovis Bio, Inc. ("Annovis").
- Each share of Series A-1 Preferred Stock automatically converted into common stock of Annovis upon the closing of the IPO at a conversion ratio of one for 0.7143.
- Each share of Series A Preferred Stock automatically converted into common stock of Annovis upon the closing of the IPO at a conversion ratio of one for 0.7143.
- The convertible notes have a maturity date of December 31, 2023. The Convertible Notes automatically converted into common stock of Annovis upon the closing of the IPO at a conversion rate equal to the principal amount of the note, plus accrued and unpaid interest, divided by $4.80 (80% of the IPO price).
Billionaire Hedge Funds
